ProShare Advisors
LUCD icon

ProShare Advisors’s Lucid Diagnostics LUCD Stock Holding History

ProShare Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Sell
13,068
-3,403
-21% -$4.33K ﹤0.01% 1845
2025
Q4 		$18K Buy
16,471
+4,320
+36% +$4.83K ﹤0.01% 2021
2025
Q3 		$12.3K Sell
12,151
-2,043
-14% -$2.23K ﹤0.01% 2002
2025
Q2 		$16.3K Buy
+14,194
New +$18.3K ﹤0.01% 2071

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

ProShare Advisors's LUCD Position: Q1 2026 in Review

ProShare Advisors reduced its Lucid Diagnostics (LUCD) stake by 21% in Q1 2026, selling an estimated $4.33K and leaving 13,068 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

ProShare Advisors first reported a position in LUCD in Q2 2025 and has held it in 4 quarters since. The position peaked at $18K in Q4 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • ProShare Advisors held 13,068 shares of Lucid Diagnostics worth $15K as of Q1 2026.
  • ProShare Advisors sold 3,403 Lucid Diagnostics shares in Q1 2026, an estimated $4.33K.
  • Lucid Diagnostics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1845 holding.
  • ProShare Advisors first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 4 quarters since.
  • ProShare Advisors's Lucid Diagnostics position peaked at $18K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.